Please assess the completion status of the following clinical trial:

Trial Title: Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Palpable splenomegaly at least 5 cm below the left costal margin~* Confirmed diagnosis of PMF or post-PV/ET MF~* Requires myelofibrosis therapy, in the opinion of the investigator~* Classified as high risk OR intermediate-2 risk as defined by the International Prognostic Scoring System (IPSS) for PMF, or intermediate-1 risk (IPSS) associated with symptomatic splenomegaly, hepatomegaly, anemia (hemoglobin \< 10.0 g/dL), and/or unresponsive to available therapy~* Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug:~  * Absolute neutrophil count (ANC) ≥ 0.75 x 10\^9/L in the absence of growth factor in the prior 7 days~ * Platelet Count ≥ 50 x 10\^9/L (≥ 100 x 10\^9/L if aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] is ≥ 2 x the upper limit of the normal range \[ULN\]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days~ * Peripheral blood blast count \< 10%~ * AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)~ * Calculated creatinine clearance (CrCL) of ≥ 45 mL/min~ * Direct bilirubin ≤ 2.0 x ULN~* Life expectancy of \> 24 weeks~* Males and females of childbearing potential must agree to use protocol-specified method(s) of contraception~* Females who are nursing must agree to discontinue nursing before the first dose of study drug~* Able to understand and willing to sign the informed consent form~Key Exclusion Criteria:~* Prior splenectomy~* Splenic irradiation within 3 months prior to the first dose of study drug~* Eligible for allogeneic bone marrow or stem cell transplantation~* Uncontrolled inter-current illness, per protocol.~* Known positive status for human immunodeficiency virus (HIV)~* Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier~* Prior use of a JAK1 or JAK2 inhibitor~* Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within 4 weeks of the first dose of study drug~* Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2~* Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Momelotinib (Type: EXPERIMENTAL): Participants will receive momelotinib plus placebo to match ruxolitinib.
- Ruxolitinib (Type: ACTIVE_COMPARATOR): Participants will receive ruxolitinib plus placebo to match momelotinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).